hydralazine has been researched along with Hyperlipoproteinemia Type II in 1 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wassmann, S | 1 |
| Czech, T | 1 |
| van Eickels, M | 1 |
| Fleming, I | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
1 other study available for hydralazine and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arterioscleros | 2004 |